Skip to Content

Aripiprazole Short-Acting Intramuscular Injection

Last Updated: July 30, 2015
Status: Current

Products Affected - Description

Abilify short-acting intramuscular injection, Otsuka America Pharmaceuticals, Inc.
7.5 mg/mL, 1.3 mL vial, 1 count (NDC 59148-0016-65)

Reason for the Shortage

  • Otsuka has discontinued Abilify short-acting intramuscular vials. The company has also discontinued the oral solution and oral disintegrating tablets.
  • There are no other suppliers of aripiprazole intramuscular short-acting injection.
  • Abilify Maintena long-acting intramuscular injection kits are not affected.
  • Abilify oral tablets and generic aripiprazole oral tablets are not affected.

Available Products

There are no presentations available.

Estimated Resupply Dates

Otsuka has discontinued Abilify short-acting intramuscular vials. There are no other suppliers of aripiprazole short-acting intramuscular injection.

Related Shortages

Updated

July 17, 23, and 30, 2015, University of Utah, Drug Information Service. Copyright 2015, Drug Information Service, University of Utah, Salt Lake City, UT.

Hide